Analysis reveals TIGIT deletion improves effector function in CAR NK-cells, suggesting potential for solid tumor therapies.
Recovery analysis and validation of TIGIT deletion in GD2.CAR-NKs after ex vivo manufacture.
No takes yet. Share an insight, caveat, or question.
Navin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: